PCN107 - BURDEN AND COSTS OF ACUTE MYELOID LEUKAEMIA IN PORTUGAL

Abstract

To estimate the burden and costs of disease attributable to acute myeloid leukaemia (AML). The analysis considers the impact of the disease in adult patients in Portugal during 2015, according to the societal perspective. The burden of disease is measured using disability adjusted life years (DALY), based on myeloid leukaemia’s data from Portuguese oncology registries and epidemiologic information from the United Kingdom. A cumulative incidence model was developed to estimate the incidence, prevalence and duration of each health state, based on a long-term clinical trial in adults with AML. Disability weights were based on the Global Burden of Disease Study. Direct costs included inpatient and outpatient services costs as well as transportation costs. Indirect costs due to productivity decrease were also included. In 2015, 207 deaths were attributable to AML, resulting in the loss of 1,340 life years due to premature death. Years lost due to disability are estimated at 51. The total burden of disease attributable to AML is estimated at 1,391 DALY, with a burden per patient of 1.96 DALY. The estimated direct costs due to AML in 2015 are about 16 million euros, with 99% of total direct costs driven by inpatient costs. Indirect costs accounted for 1.9 million euros. Overall costs are estimated at 18 million euros, with a cost per patient of 25,389 €. During 2015, AML was responsible for a burden of 1.391 DALY and a total cost of 18 million euros in mainland Portugal. Despite the low prevalence of AML, the burden of disease and cost per patient are high. This reflects the seriousness of the disease and it is a reason why it should be a focus of attention for healthcare decision makers.